KYUNG DONG PHARMACEUTICAL Co., Ltd
KKRX:0110404,900.00
KRW
-60.00
(-1.21%)
ISIN
KR7011040003
Return %
Stock
S&P 500
1Y
-15.95
14.20
3Y
-25.30
81.12
5Y
-68.99
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Gi-Sung Ryu
- Full Time Employees
- 363
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- Hwaseong-si South Korea
- IPO Date
- Dec 18, 1992
- Website
- kdpharma.co.kr
- Similar Companies
- Business
- KYUNG DONG PHARMACEUTICAL Co., Ltd. is a South Korea-based pharmaceutical manufacturing and healthcare company primarily engaged in the research, development, production, and commercialization of ethical prescription pharmaceuticals, over-the-counter medications, active pharmaceutical ingredients, and health functional foods. Founded in 1975 and headquartered in Gwacheon-si, Gyeonggi-do, South Korea, the company operates central research institutes and automated manufacturing facilities in Hwaseong-si, Gyeonggi-do, distributing its products domestically to hospitals, clinics, and pharmacies, as well as exporting active raw materials and finished dosage forms to international markets across Asia, Europe, Latin America, and the Middle East. The company operates across four primary product and service segments, comprising Prescription Pharmaceuticals, Over-the-Counter Pharmaceuticals, Active Pharmaceutical Ingredients, and Health Functional Foods. Its core offerings include: cardiovascular and circulatory medicines for hypertension, hyperlipidemia, and thrombosis; gastrointestinal therapeutics including proton pump inhibitors, antacids, and anti-ulcer treatments; central nervous system agents for neurological and psychiatric disorders; endocrine and metabolic treatments for diabetes and obesity; musculoskeletal, analgesic, and non-steroidal anti-inflammatory drugs; respiratory and anti-allergic formulations; urological and renal medications; anti-infectives and antibiotics; over-the-counter consumer healthcare remedies featuring its flagship Gnal-N brand family of pain relievers, cold medicines, and antipyretics, alongside digestives, topical plasters, and vitamin complexes; chemical synthesis and global supply of high-purity active pharmaceutical ingredients; and dietary supplements, probiotics, and wellness products marketed through domestic retail channels and its KDmoment consumer commerce platform. In recent operational and strategic developments, Kyung Dong Pharmaceutical has accelerated its business transformation toward biopharmaceuticals, open innovation, and commercial modernization. The company entered into a strategic co-development partnership with synthetic biology company Asimov to engineer next-generation biosimilar antibody therapeutics, while advancing preclinical development on a biosimilar for dupilumab. Under its open-innovation initiative, the company maintains active co-development alliances with specialized biotechnology ventures, including partnerships with Aulbio to develop long-acting sustained-release injectable therapies for prostate cancer, precocious puberty, diabetes, and obesity; Innopharmascreen for immuno-oncology therapies targeting non-small cell lung cancer; P2K Bio for ophthalmic treatments targeting dry eye syndrome and the domestic localization of essential drug raw materials; and Protium Science for oral antibody drug formulations. To enhance operational efficiency and manufacturing capacity, Kyung Dong Pharmaceutical transitioned its domestic pharmaceutical distribution model toward contract sales organization networks, expanded its direct-to-consumer digital commerce operations, and commenced development of a cGMP-compliant modular smart factory in Hwaseong to support upcoming clinical and commercial biopharmaceutical production. Additionally, the company is actively pursuing global market expansion through technology transfer and local manufacturing infrastructure initiatives in Central Asia and the broader Eurasian region.